No biomarker
|
Maxillary Sinus Carcinoma
|
No biomarker
|
Maxillary Sinus Carcinoma
|
VC Sensitive: A2 - Guideline
|
VC Sensitive: A2 - Guideline
|
No biomarker
|
Maxillary Sinus Carcinoma
|
No biomarker
|
Maxillary Sinus Carcinoma
|
EP Sensitive: A2 - Guideline
|
EP Sensitive: A2 - Guideline
|
No biomarker
|
Maxillary Sinus Carcinoma
|
No biomarker
|
Maxillary Sinus Carcinoma
|
CAV Sensitive: A2 - Guideline
|
CAV Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Maxillary Sinus Carcinoma
|
MSI-H/dMMR
|
Maxillary Sinus Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Maxillary Sinus Carcinoma
|
No biomarker
|
Maxillary Sinus Carcinoma
|
pembrolizumab + cetuximab Sensitive: A2 - Guideline
|
pembrolizumab + cetuximab Sensitive: A2 - Guideline
|
No biomarker
|
Maxillary Sinus Carcinoma
|
No biomarker
|
Maxillary Sinus Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|